Pharnext to Attend January Investor Conferences
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that senior management will be attending the following conferences taking place in January in France:
- Oddo 20 th Midcap Forum on January 5-6 in Lyon Convention Center
- Invest Securities BioMed Event – 2nd Edition - on January 26 in Salons Hoche, Paris
If you are interested in meeting the Pharnext management team during either of these events, please send an email to email@example.com .
Senior management will also be available for meetings in the U.S. in San Francisco, CA from January 9-13 during the 35th Annual J.P. Morgan Healthcare Conference . If you are interested in meeting the Pharnext management team, please send an email to Sarah McCabe at firstname.lastname@example.org .
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY© . The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG© might offer several key advantages: efficacy, safety, and robust intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
PLEODRUG© and PLEOTHERAPY© are registered trademarks by Pharnext
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investors Relations (Europe)
Julie Coulot, +33 (0)1 44 71 20 40
Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1-212-362-1200
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Tony Russo, Ph.D., +1-212-845-4251
Matt Middleman, M.D., +1-212-845-4272
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
PROSUME23.9.2017 10:02 | pressemeddelelse
How to Share New Energy Models Through Blockchain?
MA-ICP-GROUP22.9.2017 22:23 | pressemeddelelse
California Sports Surfaces Announces New Senior Leadership
CQN-SMITHS-DETECTION22.9.2017 18:04 | pressemeddelelse
CORRECTING and REPLACING Smiths Detection Wins Biggest Ever Single Order for Next-Generation Hold Baggage Scanner for Frankfurt Airport
MA-ICP-CONSTRUCTION22.9.2017 16:39 | pressemeddelelse
California Sports Surfaces’ Rebound Ace Portable Court to be Used at Inaugural Laver Cup
SMITHS-DETECTION22.9.2017 13:02 | pressemeddelelse
Smiths Detection is Supplying the Latest Technology for ECAC Standard 3 EDS Upgrade at Frankfurt Airport
VESPA-INTERACTIVE22.9.2017 13:02 | pressemeddelelse
Mobile RPG ‘King’s Raid’ Set to Launch in European Markets
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum